Gastroesophageal reflux disease: Presentation and assessment of a common, challenging disorder

Clinical Cornerstone

Volumn 5, Issue 4, 2003, Pages 2-14

  Soll, Andrew H ^a   Fass, Ronnie ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANEMIA; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE SEVERITY; DYSPHAGIA; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS MANOMETRY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HEARTBURN; HIATUS HERNIA; HUMAN; REFLUX ESOPHAGITIS; SOCIAL PSYCHOLOGY; SYMPTOMATOLOGY; THORAX PAIN; WEIGHT REDUCTION;

EID: 1842840190     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(03)90095-0     Document Type: Article

References (29)

1. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease - current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-314.
2. Martinez SD, Malagon IB, Garewal HS, et al. Nonerosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537-545.
3. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol. 1997;32:974-979.
4. Watson RG, Tham TC, Johnston BT, McDougall NI. Double-blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the "sensitive oesophagus." Gut. 1997;40:587-590.
5. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-1909.
6. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol. 1997;92:37-41.
7. McDougall NI, Johnston BT, Collins JS, et al. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol. 1997;9: 1161-1167.
8. Srinivasan R, Katz PO, Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: Feasible and effective. Aliment Pharmacol Ther. 2001;15:519-524.
9. Manabe N, Yoshihara M, Sasaki A, et al. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol. 2002;17:949-954.
10. Locke GR III. Natural history of nonerosive reflux disease. Is all gastroesophageal reflux disease the same? What is the evidence? Gastroenterol Clin North Am. 2002;31:S59-S66.
11. Orlando RC. Pathogenesis of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2002;31:S35-S44.
12. Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol. 2001;96:1711-1717.
13. Kahrilas PJ, Pandolfino JE. Gastroesophageal reflux disease and its complications, including Barrett's metaplasia. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fortran's Gastrointestinal and Liver Disease. 7th ed. Philadelphia, Pa: WB Saunders Co; 2002:599-622.
14. Jenkinson LR, Norris TL, Watson A. Gastro-oesophageal reflux associated with nifedipine. Aliment Pharmacol Ther. 1988;2:337-339.
15. Kahan A, Bour B, Couturier D, et al. Nifedipine and esophageal dysfunction in progressive systemic sclerosis. A controlled manometric study. Arthritis Rheum. 1985;28:490-495.
16. Vaughan TL, Farrow DC, Hansten PD, et al. Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev. 1998;7:749-756.
17. Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD. Gastro-oesophageal reflux disease in obesity: Pathophysiological and therapeutic considerations. Obes Rev. 2002;3:9-15.
18. Ouatu-Lascar R, Lin OS, Fitzgerald RC, Triadafilopoulos G. Upright versus supine reflux in gastroesophageal. reflux disease. J Gastroenterol Hepatol. 2001;16:1184-1190.
19. Tutuian R, Vela MF, Shay SS, Castell DO. Multi-channel intraluminal impedance in esophageal function testing and gastroesophageal reflux monitoring. J Clin Gastroenterol. 2003;37:206-215.
20. Trimble KC, Douglas S, Heading RC. Twenty-four-hour esophageal pH monitoring: Technique and application. Gastroenterologist. 1995;3: 187-198.
21. McDonald-Haile J, Bradley LA, Bailey MA, et al. Relaxation training reduces symptom reports and acid exposure in patients with gastroesophageal reflux disease. Gastroenterology. 1994;107:61-69.
22. Baker LH, Lieberman D, Oehlke M. Psychological distress in patients with gastroesophageal reflux disease. Am J Gastroenterol. 1995;90:1797-1803.
23. Meyer JH, Lembo A, Elashoff JD, et al. Duodenal fat intensifies the perception of heartburn. Gut. 2001;49:624-628.
24. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology. 1998;115:42-49.
25. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole. Gastroenterology. 2001;120:1599-1606.
26. Soll AH. Peptic ulcer and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Gastrointestinal Disease. Philadelphia, Pa: WB Saunders Co; 1997:620-678.
27. Goodman AJ, Kerrigan DD, Johnson AG. Effect of the pre-operative response to H2 receptor antagonists on the outcome of highly selective vagotomy for duodenal ulcer. Br J Surg. 1987;74:897-899.
28. Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med. 1999;107:41S-50S.
29. Jackson JL, Kroenke K. Difficult patient encounters in the ambulatory clinic: Clinical predictors and outcomes. Arch Intern Med. 1999;159:1069-1075.